<p>Drug firm Mankind Pharma on Thursday said it had received the licence from the Defence Research and Development Organisation (DRDO) to manufacture and market oral 2-Deoxy-D-Glucose (2-DG), which is used for the treatment of Covid-19. </p>.<p>The drug was developed by the Defence Research and Development Establishment, Gwalior. The clinical trials were conducted by the Institute of Nuclear Medicine and Allied Sciences, a DRDO lab, in association with Dr Reddy's Laboratories, said Mankind Pharma in a statement. </p>.<p><strong>Read: <a href="https://www.deccanherald.com/business/economy-business/india-supercharged-its-economy-30-years-ago-covid-19-unravelled-it-in-months-1006253.html">How Covid-19 unravelled India's economy in months</a></strong></p>.<p>The company would manufacture the product at its facilities in Visakhapatnam and Himachal Pradesh, the statement said.</p>.<p>The office of the Drugs Controller General of India on May 1 had permitted the emergency use of 2-DG as an adjunct treatment for moderate to severe Covid-19 patients, Mankind Pharma said.</p>.<p>The drug is found to help hospitalised Covid-19 patients recover faster and is known to reduce the supplemental oxygen dependency among Covid-19 patients, the company said.</p>.<p>"Our objective behind this agreement is to ensure maximum reach of this medication to the deserving Indian patients suffering from the deadly pandemic," the company added.</p>
<p>Drug firm Mankind Pharma on Thursday said it had received the licence from the Defence Research and Development Organisation (DRDO) to manufacture and market oral 2-Deoxy-D-Glucose (2-DG), which is used for the treatment of Covid-19. </p>.<p>The drug was developed by the Defence Research and Development Establishment, Gwalior. The clinical trials were conducted by the Institute of Nuclear Medicine and Allied Sciences, a DRDO lab, in association with Dr Reddy's Laboratories, said Mankind Pharma in a statement. </p>.<p><strong>Read: <a href="https://www.deccanherald.com/business/economy-business/india-supercharged-its-economy-30-years-ago-covid-19-unravelled-it-in-months-1006253.html">How Covid-19 unravelled India's economy in months</a></strong></p>.<p>The company would manufacture the product at its facilities in Visakhapatnam and Himachal Pradesh, the statement said.</p>.<p>The office of the Drugs Controller General of India on May 1 had permitted the emergency use of 2-DG as an adjunct treatment for moderate to severe Covid-19 patients, Mankind Pharma said.</p>.<p>The drug is found to help hospitalised Covid-19 patients recover faster and is known to reduce the supplemental oxygen dependency among Covid-19 patients, the company said.</p>.<p>"Our objective behind this agreement is to ensure maximum reach of this medication to the deserving Indian patients suffering from the deadly pandemic," the company added.</p>